A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV.

Trial Profile

A Phase I Study of OSI-774 in Combination With Standard Fractionation Radiation Therapy in Patients With Oral Cavity or Oropharyngeal Cancer Stage II or III and in Combination With Standard Fractionation Radiation Therapy and Low Dose Daily Cisplatin in Patients With Oral Cavity or Oropharyngeal Cancer Stage III and IV.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2013

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin
  • Indications Orofacial cancer; Oropharyngeal cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jan 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 15 Aug 2011 Planned end date 1 May 2011 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top